| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 7741.T - HOYA Corporation | BUY | 4,000 @ JPY 147.616 | JPY 590,464 | The ETF bought 4000 new shares of 7741.T (HOYA Corporation). The shares were bought for an average price of 147.616 compared to the previous average buy price of 140.514. This is 5.1% higher than average price of previous purchases of 7741.T. |
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 16.8312 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 16.8312. The average price that 2413.T shares were previous bought at was JPY 14.2936. The current market price is 17.8% higher than average price they were purchased at. The value of the holding in 2413.T has increased by JPY 28,854 compared to the previous valuation of M3, Inc. however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 16.4 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 16.4. The average price that 4151.T shares were previous bought at was JPY 15.6107. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in 4151.T has increased by JPY 65,487 compared to the previous valuation of Kyowa Kirin Co., Ltd. however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 28.3415 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 28.3415. The average price that 4502.T shares were previous bought at was JPY 28.7904. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 3,751 compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.2272 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.2272. The average price that 4507.T shares were previous bought at was JPY 16.8555. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in 4507.T has fallen by JPY 222 compared to the previous valuation of Shionogi & Co., Ltd. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.8745 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.8745. The average price that 4523.T shares were previous bought at was JPY 30.2753. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 15,109 compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 15.7133 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 15.7133. The average price that 4543.T shares were previous bought at was JPY 16.6368. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in 4543.T has increased by JPY 16,001 compared to the previous valuation of Terumo Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 54.722 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 54.722. The average price that 4578.T shares were previous bought at was JPY 53.253. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 17,085 compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.95497 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.95497. The average price that 6869.T shares were previous bought at was JPY 12.6105. The current market price is -21.1% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 91,723 compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 13.2318 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 13.2318. The average price that 7733.T shares were previous bought at was JPY 12.5576. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in 7733.T has increased by JPY 14,550 compared to the previous valuation of Olympus Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 151.25 | USD 0 | The current share valuation price of A based on adjusted close was USD 151.25. The average price that A shares were previous bought at was USD 134.498. The current market price is 12.5% higher than average price they were purchased at. The value of the holding in A has increased by USD 555,150 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 236.28 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 236.28. The average price that ABBV shares were previous bought at was USD 200.201. The current market price is 18.0% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 868,769 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 128.11 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 128.11. The average price that ABT shares were previous bought at was USD 131.923. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in ABT has increased by USD 341,670 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 76.0279 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 76.0279. The average price that ALC.SW shares were previous bought at was CHF 77.7293. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in ALC.SW has increased by CHF 79,452 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ALGN - Align Technology Inc | HOLD | 0 @ USD 142.56 | USD 0 | The current share valuation price of ALGN based on adjusted close was USD 142.56. The average price that ALGN shares were previous bought at was USD 138.959. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in ALGN has increased by USD 17,911 compared to the previous valuation of Align Technology Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 436.38 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 436.38. The average price that ALNY shares were previous bought at was USD 414.462. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in ALNY has fallen by USD 72,626 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 337.54 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 337.54. The average price that AMGN shares were previous bought at was USD 290.429. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 40,842 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 920.58 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 920.58. The average price that ARGX.BR shares were previous bought at was EUR 717.419. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in ARGX.BR has fallen by EUR 9,980 compared to the previous valuation of Argenx SE |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 180.849 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 180.849. The average price that AZN.L shares were previous bought at was GBP 159.117. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 380,576 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 18.31 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 18.31. The average price that BAX shares were previous bought at was USD 22.4144. The current market price is -18.3% lower than average price they were purchased at. The value of the holding in BAX has increased by USD 9,411 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 31.7269 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 31.7269. The average price that BAYN.DE shares were previous bought at was EUR 31.2099. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 12,063 compared to the previous valuation of Bayer AG however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 192.72 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 192.72. The average price that BDX shares were previous bought at was USD 182.974. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in BDX has increased by USD 18,981 compared to the previous valuation of Becton Dickinson and Company however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 175.3 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 175.3. The average price that BIIB shares were previous bought at was USD 145.122. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 21,019 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 123.871 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 123.871. The average price that BIM.PA shares were previous bought at was EUR 129.938. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 3,522 compared to the previous valuation of BioMerieux however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 54.6901 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 54.6901. The average price that BMRN shares were previous bought at was USD 56.2712. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in BMRN has increased by USD 9,307 compared to the previous valuation of Biomarin Pharmaceutical Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 46.25 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 46.25. The average price that BMY shares were previous bought at was USD 47.135. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in BMY has increased by USD 26,960 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 96.88 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.88. The average price that BSX shares were previous bought at was USD 101.285. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 9,146 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 96.88 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.88. The average price that BSX shares were previous bought at was USD 101.285. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 9,146 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 209.48 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 209.48. The average price that CAH shares were previous bought at was USD 167.417. The current market price is 25.1% higher than average price they were purchased at. The value of the holding in CAH has increased by USD 118,274 compared to the previous valuation of Cardinal Health Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 278.09 | USD 0 | The current share valuation price of CI based on adjusted close was USD 278.09. The average price that CI shares were previous bought at was USD 291.006. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in CI has increased by USD 369,477 compared to the previous valuation of Cigna Corp however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 36.5 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 36.5. The average price that CNC shares were previous bought at was USD 38.4416. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in CNC has increased by USD 197,186 compared to the previous valuation of Concurrent Technologies Plc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| COH.AX - | HOLD | 0 @ AUD 171.833 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 171.833. The average price that COH.AX shares were previous bought at was AUD 185.84. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in COH.AX has fallen by AUD 69,873 compared to the previous valuation of |
| COLO-B.CO - | HOLD | 0 @ DKK 89.3461 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 89.3461. The average price that COLO-B.CO shares were previous bought at was DKK 92.4036. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in COLO-B.CO has increased by DKK 15,419 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 75.47 | USD 0 | The current share valuation price of COO based on adjusted close was USD 75.47. The average price that COO shares were previous bought at was USD 70.4094. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in COO has increased by USD 17,449 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 365.68 | USD 0 | The current share valuation price of COR based on adjusted close was USD 365.68. The average price that COR shares were previous bought at was USD 320.421. The current market price is 14.1% higher than average price they were purchased at. The value of the holding in COR has increased by USD 177,962 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 115.081 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 115.081. The average price that CSL.AX shares were previous bought at was AUD 133.24. The current market price is -13.6% lower than average price they were purchased at. The value of the holding in CSL.AX has fallen by AUD 4,294 compared to the previous valuation of |
| CVS - CVS Health Corp | HOLD | 0 @ USD 78.03 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 78.03. The average price that CVS shares were previous bought at was USD 68.9166. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in CVS has increased by USD 119,135 compared to the previous valuation of CVS Health Corp however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 33.0774 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 33.0774. The average price that DEMANT.CO shares were previous bought at was DKK 36.0082. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in DEMANT.CO has increased by DKK 6,339 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 191.25 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 191.25. The average price that DGX shares were previous bought at was USD 180.134. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in DGX has increased by USD 8,045 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 227.39 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 227.39. The average price that DHR shares were previous bought at was USD 198.961. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 161,207 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 227.39 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 227.39. The average price that DHR shares were previous bought at was USD 198.961. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 161,207 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 218.528 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 218.528. The average price that DIM.PA shares were previous bought at was EUR 220.724. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in DIM.PA has increased by EUR 5,304 compared to the previous valuation of Sartorius Stedim Biotech however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| DVA - DaVita HealthCare Partners Inc | HOLD | 0 @ USD 120.25 | USD 0 | The current share valuation price of DVA based on adjusted close was USD 120.25. The average price that DVA shares were previous bought at was USD 128.823. The current market price is -6.7% lower than average price they were purchased at. The value of the holding in DVA has increased by USD 9,575 compared to the previous valuation of DaVita HealthCare Partners Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 60.23 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 60.23. The average price that DXCM shares were previous bought at was USD 71.2254. The current market price is -15.4% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 18,775 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 351.946 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 351.946. The average price that EL.PA shares were previous bought at was EUR 319.485. The current market price is 10.2% higher than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 59,435 compared to the previous valuation of EssilorLuxottica SA |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 321.73 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 321.73. The average price that ELV shares were previous bought at was USD 335.766. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in ELV has increased by USD 319,917 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 321.73 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 321.73. The average price that ELV shares were previous bought at was USD 335.766. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in ELV has increased by USD 319,917 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 66.4557 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 66.4557. The average price that ERF.PA shares were previous bought at was EUR 69.5125. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 1,309 compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 85.13 | USD 0 | The current share valuation price of EW based on adjusted close was USD 85.13. The average price that EW shares were previous bought at was USD 78.715. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in EW has increased by USD 128,781 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 46.6271 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 46.6271. The average price that FME.DE shares were previous bought at was EUR 51.1715. The current market price is -8.9% lower than average price they were purchased at. The value of the holding in FME.DE has increased by EUR 5,153 compared to the previous valuation of Fresenius Medical Care AG however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| FPH.NZ - | HOLD | 0 @ NZD 20.6325 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 20.6325. The average price that FPH.NZ shares were previous bought at was NZD 21.1379. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in FPH.NZ has fallen by NZD 2,507 compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 53.988 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 53.988. The average price that FRE.DE shares were previous bought at was EUR 52.3188. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 632 compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 182.65 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 182.65. The average price that GALD.SW shares were previous bought at was CHF 173.382. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in GALD.SW has fallen by CHF 5,909 compared to the previous valuation of |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 76.45 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 76.45. The average price that GEHC shares were previous bought at was USD 75.2601. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in GEHC has increased by USD 16,036 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 126.64 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 126.64. The average price that GILD shares were previous bought at was USD 116.15. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 253,337 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 303.056 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 303.056. The average price that GMAB.CO shares were previous bought at was DKK 280.97. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 22,694 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 11.6683 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 11.6683. The average price that GRF.MC shares were previous bought at was EUR 13.2982. The current market price is -12.3% lower than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 513 compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.3978 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.3978. The average price that GSK.L shares were previous bought at was GBP 21.5231. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 29,704 compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 491 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 491. The average price that HCA shares were previous bought at was USD 434.61. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in HCA has increased by USD 58,365 compared to the previous valuation of HCA Holdings Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 20.8722 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.8722. The average price that HIK.L shares were previous bought at was GBP 24.0663. The current market price is -13.3% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 4,304 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.93604 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.93604. The average price that HLN.L shares were previous bought at was GBP 4.93096. The current market price is 0.1% higher than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 17,940 compared to the previous valuation of Haleon PLC however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.36 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.36. The average price that HOLX shares were previous bought at was USD 69.7374. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 21,628 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 227.1 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 227.1. The average price that HUM shares were previous bought at was USD 267.564. The current market price is -15.1% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 70,942 compared to the previous valuation of Hummingbird Resources PLC however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| HUM - Humana Inc | HOLD | 0 @ USD 227.1 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 227.1. The average price that HUM shares were previous bought at was USD 267.564. The current market price is -15.1% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 70,942 compared to the previous valuation of Humana Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 725.91 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 725.91. The average price that IDXX shares were previous bought at was USD 609.637. The current market price is 19.1% higher than average price they were purchased at. The value of the holding in IDXX has increased by USD 582,510 compared to the previous valuation of IDEXX Laboratories Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 123.85 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 123.85. The average price that ILMN shares were previous bought at was USD 101.567. The current market price is 21.9% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 14,343 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 102.06 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 102.06. The average price that INCY shares were previous bought at was USD 86.8418. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in INCY has increased by USD 1,083 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 146.184 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 146.184. The average price that IPN.PA shares were previous bought at was EUR 135.358. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 166 compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 224.9 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 224.9. The average price that IQV shares were previous bought at was USD 195.252. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 396,869 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 561.61 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 561.61. The average price that ISRG shares were previous bought at was USD 530.514. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 187,684 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 203.9 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 203.9. The average price that JNJ shares were previous bought at was USD 167.619. The current market price is 21.6% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 119,621 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 265.64 | USD 0 | The current share valuation price of LH based on adjusted close was USD 265.64. The average price that LH shares were previous bought at was USD 262.344. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in LH has increased by USD 7,048 compared to the previous valuation of Laboratory Corporation of America Holdings however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1059.7 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1059.7. The average price that LLY shares were previous bought at was USD 802.425. The current market price is 32.1% higher than average price they were purchased at. The value of the holding in LLY has increased by USD 1,025,346 compared to the previous valuation of Eli Lilly and Company however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 661.349 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 661.349. The average price that LONN.SW shares were previous bought at was CHF 677.655. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 6,209 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MCK - McKesson Corporation | HOLD | 0 @ USD 866.03 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 866.03. The average price that MCK shares were previous bought at was USD 778.024. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 345,120 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 101.2 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 101.2. The average price that MDT shares were previous bought at was USD 91.9031. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 50,513 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MOH - MOH | HOLD | 0 @ USD 141.56 | USD 0 | The current share valuation price of MOH based on adjusted close was USD 141.56. The average price that MOH shares were previous bought at was USD 200.253. The current market price is -29.3% lower than average price they were purchased at. The value of the holding in MOH has increased by USD 103,275 compared to the previous valuation of MOH however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MOH - LVMH Moët Hennessy - Louis Vuitton Société Européenne | HOLD | 0 @ USD 141.56 | USD 0 | The current share valuation price of MOH based on adjusted close was USD 141.56. The average price that MOH shares were previous bought at was USD 200.253. The current market price is -29.3% lower than average price they were purchased at. The value of the holding in MOH has increased by USD 103,275 compared to the previous valuation of LVMH Moët Hennessy - Louis Vuitton Société Européenne however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 97.76 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 97.76. The average price that MRK shares were previous bought at was USD 79.8418. The current market price is 22.4% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 398,253 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 97.76 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 97.76. The average price that MRK shares were previous bought at was USD 79.8418. The current market price is 22.4% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 398,253 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 129.162 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 129.162. The average price that MRK.DE shares were previous bought at was EUR 130.471. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 4,339 compared to the previous valuation of Merck KGaA however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1452.35 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1452.35. The average price that MTD shares were previous bought at was USD 1320.86. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in MTD has increased by USD 22,182 compared to the previous valuation of Mettler-Toledo International Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1452.35 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1452.35. The average price that MTD shares were previous bought at was USD 1320.86. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in MTD has increased by USD 22,182 compared to the previous valuation of AMUNDI EUR GOV 710 however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 141.83 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 141.83. The average price that NBIX shares were previous bought at was USD 140.213. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 6,318 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 127.224 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 127.224. The average price that NOVN.SW shares were previous bought at was CHF 123.74. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 680,466 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 46.9136 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 46.9136. The average price that NOVO-B.CO shares were previous bought at was DKK 55.9384. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has fallen by DKK 514,502 compared to the previous valuation of Novo Nordisk A/S |
| NTRA - Natera Inc | HOLD | 0 @ USD 230.63 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 230.63. The average price that NTRA shares were previous bought at was USD 171.24. The current market price is 34.7% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 15,549 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 68.9514 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 68.9514. The average price that ORNBV.HE shares were previous bought at was EUR 67.7895. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 117 compared to the previous valuation of Orion Oyj however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.04 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.04. The average price that PFE shares were previous bought at was USD 24.6309. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 136,492 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 27.017 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 27.017. The average price that PHIA.AS shares were previous bought at was EUR 26.5139. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in PHIA.AS has increased by EUR 1,480 compared to the previous valuation of Koninklijke Philips NV however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 161.712 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 161.712. The average price that PME.AX shares were previous bought at was AUD 182.072. The current market price is -11.2% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 3,208 compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 331.17 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 331.17. The average price that PODD shares were previous bought at was USD 311.94. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in PODD has increased by USD 25,939 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 46.4431 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 46.4431. The average price that QIA.DE shares were previous bought at was EUR 45.6658. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in QIA.DE has increased by EUR 84,602 compared to the previous valuation of QIAGEN NV however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 58.3701 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 58.3701. The average price that REC.MI shares were previous bought at was EUR 58.4756. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 1,040 compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 755.9 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 755.9. The average price that REGN shares were previous bought at was USD 597.184. The current market price is 26.6% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 59,705 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| RMD - ResMed Inc | HOLD | 0 @ USD 250.75 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 250.75. The average price that RMD shares were previous bought at was USD 262.755. The current market price is -4.6% lower than average price they were purchased at. The value of the holding in RMD has increased by USD 21,351 compared to the previous valuation of ResMed Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 403.388 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 403.388. The average price that RO.SW shares were previous bought at was CHF 342.541. The current market price is 17.8% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 31,497 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 390.28 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 390.28. The average price that ROG.SW shares were previous bought at was CHF 326.825. The current market price is 19.4% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 92,289 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 38.92 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 38.92. The average price that RPRX shares were previous bought at was USD 36.5917. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 4,321 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 98.2699 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 98.2699. The average price that RVTY shares were previous bought at was USD 91.7581. The current market price is 7.1% higher than average price they were purchased at. The value of the holding in RVTY has increased by USD 13,273 compared to the previous valuation of Revvity Inc. however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 99.281 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 99.281. The average price that SAN.PA shares were previous bought at was EUR 98.7196. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 21,626 compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 67.6931 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 67.6931. The average price that SDZ.SW shares were previous bought at was CHF 57.5322. The current market price is 17.7% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 14,140 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 14.8573 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 14.8573. The average price that SHL.AX shares were previous bought at was AUD 14.922. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in SHL.AX has increased by AUD 916 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 48.0417 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 48.0417. The average price that SHL.DE shares were previous bought at was EUR 53.6245. The current market price is -10.4% lower than average price they were purchased at. The value of the holding in SHL.DE has increased by EUR 3,143 compared to the previous valuation of Siemens Healthineers AG however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SIG.AX - | HOLD | 0 @ AUD 1.89818 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.89818. The average price that SIG.AX shares were previous bought at was AUD 1.98246. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in SIG.AX has fallen by AUD 867 compared to the previous valuation of |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.3706 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.3706. The average price that SN.L shares were previous bought at was GBP 17.3473. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in SN.L has increased by GBP 4,271 compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 34.8069 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 34.8069. The average price that SOBI.ST shares were previous bought at was SEK 31.3147. The current market price is 11.2% higher than average price they were purchased at. The value of the holding in SOBI.ST has fallen by SEK 488 compared to the previous valuation of |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 82.9 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 82.9. The average price that SOLV shares were previous bought at was USD 72.0872. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in SOLV has increased by USD 12,885 compared to the previous valuation of Solventum Corp. however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SOON.SW - | HOLD | 0 @ CHF 241.019 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 241.019. The average price that SOON.SW shares were previous bought at was CHF 277.372. The current market price is -13.1% lower than average price they were purchased at. The value of the holding in SOON.SW has increased by CHF 12,333 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 259.129 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 259.129. The average price that SRT3.DE shares were previous bought at was EUR 254.653. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 25,235 compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| STE - STERIS plc | HOLD | 0 @ USD 263.29 | USD 0 | The current share valuation price of STE based on adjusted close was USD 263.29. The average price that STE shares were previous bought at was USD 240.814. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in STE has increased by USD 246,892 compared to the previous valuation of STERIS plc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 119.434 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 119.434. The average price that STMN.SW shares were previous bought at was CHF 117.022. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in STMN.SW has increased by CHF 2,732 compared to the previous valuation of however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| SYK - Stryker Corporation | HOLD | 0 @ USD 368.27 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 368.27. The average price that SYK shares were previous bought at was USD 370.895. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in SYK has increased by USD 55,239 compared to the previous valuation of Stryker Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 24.21 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 24.21. The average price that TEVA shares were previous bought at was USD 18.796. The current market price is 28.8% higher than average price they were purchased at. The value of the holding in TEVA has fallen by USD 1,736 compared to the previous valuation of Teva Pharma Industries Ltd ADR |
| TMO - Time Out Group plc | HOLD | 0 @ USD 587.48 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 587.48. The average price that TMO shares were previous bought at was USD 476.092. The current market price is 23.4% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 313,918 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 267.985 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 267.985. The average price that UCB.BR shares were previous bought at was EUR 248.44. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 82,246 compared to the previous valuation of UCB SA however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 319.97 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 319.97. The average price that UNH shares were previous bought at was USD 320.878. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in UNH has increased by USD 521,278 compared to the previous valuation of UnitedHealth Group Incorporated however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 474.82 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 474.82. The average price that UTHR shares were previous bought at was USD 415.643. The current market price is 14.2% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 89 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 244.06 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 244.06. The average price that VEEV shares were previous bought at was USD 284.797. The current market price is -14.3% lower than average price they were purchased at. The value of the holding in VEEV has fallen by USD 735,561 compared to the previous valuation of Veeva Systems Inc Class A |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 426.76 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 426.76. The average price that VRTX shares were previous bought at was USD 423.38. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in VRTX has increased by USD 163,064 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| WAT - Waters Corporation | HOLD | 0 @ USD 393.99 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 393.99. The average price that WAT shares were previous bought at was USD 337.329. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 316,191 compared to the previous valuation of Waters Corporation however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 393.99 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 393.99. The average price that WAT shares were previous bought at was USD 337.329. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 316,191 compared to the previous valuation of MULETFWATIMETFP however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 271.07 | USD 0 | The current share valuation price of WST based on adjusted close was USD 271.07. The average price that WST shares were previous bought at was USD 263.689. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in WST has increased by USD 19,924 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 92.1801 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 92.1801. The average price that ZBH shares were previous bought at was USD 97.5107. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in ZBH has increased by USD 13,040 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 122.06 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 122.06. The average price that ZTS shares were previous bought at was USD 140.053. The current market price is -12.8% lower than average price they were purchased at. The value of the holding in ZTS has increased by USD 527,862 compared to the previous valuation of Zoetis Inc however if the holding was sold on 2025-11-21 this would crystalise an overall loss. |
| 4568.T - Daiichi Sankyo Company, Limited | SELL | -30,200 @ JPY 23.6339 | JPY -713,744 | The ETF sold 30200 shares of 4568.T on 2025-11-21. The shares were previously bought for an average price of JPY 24.0521. The Daiichi Sankyo Company, Limited shares were sold for -1.7% lower than average price of previous purchases. This resulted in an overall loss of JPY 12,630 The average price that the ETF previously sold 4568.T share for is JPY 25.8123 which is higher than the selling price of JPY 23.6339 on 2025-11-21. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | SELL | -18,400 @ JPY 53.4509 | JPY -983,497 | The ETF sold 18400 shares of 4519.T on 2025-11-21. The shares were previously bought for an average price of JPY 46.3112. The Chugai Pharmaceutical Co., Ltd. shares were sold for 15.4% higher than average price of previous purchases. This sale made a profit of JPY 131,370 The average price that the ETF previously sold 4519.T share for is JPY 49.2563 so the ETF has sold 18400 shares on 2025-11-21 at a higher price than the previous selling average. |
| 4503.T - Astellas Pharma Inc. | SELL | -211,800 @ JPY 12.5483 | JPY -2,657,730 | The ETF sold 211800 shares of 4503.T on 2025-11-21. The shares were previously bought for an average price of JPY 10.7471. The Astellas Pharma Inc. shares were sold for 16.8% higher than average price of previous purchases. This sale made a profit of JPY 381,494 The average price that the ETF previously sold 4503.T share for is JPY 10.1287 so the ETF has sold 211800 shares on 2025-11-21 at a higher price than the previous selling average. |